The significance of hypofibrinolysis for the risk of recurrence of venous thromboembolism

Thrombosis and Haemostasis

Volumn 75, Issue 4, 1996, Pages 607-611

  Schulman, S ^a,b   Wiman, B ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APEKUMAROL; DICOUMAROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; WARFARIN;

ADOLESCENT; ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FIBRINOLYSIS; HUMAN; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STATISTICAL ANALYSIS; THROMBOEMBOLISM; VEIN OCCLUSION; VEIN THROMBOSIS;

EID: 0029880730     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650330     Document Type: Article

References (26)

1. The British Committee for Standards in Haematology. Guidelines on the investigation and management of thrombophilia. J Clin Pathol 1990; 43: 703-9.
2. Tengborn L. Laboratory investigation of fibrinolytic and other haemostatic risk factors in patients with venous thromboembolism. In: Clinical aspects of fibrinolysis. Nilsson TK, Boman K, Jansson JH, eds. Almqvist & Wiksell International, Stockholm 1991: 67-84.
3. Prins MH, Hirsh J. A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism Arch Intern Med 1991; 151: 1721-31.
4. Korninger C, Lechner K, Niessner H, Gössinger H, Kundi M. Impaired fibrinolytic capacity predisposes for recurrence of venous thrombosis. Thromb Haemost 1984; 52: 127-30.
5. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Shen C. Newcomer LM, Goldhaber SZ, Hennekens CH. Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor. Circulation 1992; 85: 1822-7.
6. Wilmelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-5.
7. Meade TW, North WRS, Chakrabarti R, Stirling Y, Haines AP, Thompson SG. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet 1980; 1: 10504.
8. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-9.
9. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165-8.
10. Jansson J-H, Olofsson B-O, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease: a 7-year follow-up. Circulation 1993; 88: 2030-4.
11. Prins MH, Hirsh J. A critical review of the relationship between impaired fibrinolysis and myocardial infarction. Am Heart J 1991; 122: 545-51.
12. Schulman S, Rhedin A-S, Lindmarker P, Carlsson A, Lärfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H, Viering S, Nordlander S, Leijd B, Jönsson K-Å, Hjorth M, Linder O, Boberg J and The DURAC Trial Study Group. A comparison of six weeks and six months of oral anti-coagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332: 1661-5.
13. Rabinov K, Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Arch Surg 1972; 104: 134-44.
14. Chmielewska J, Wiman B. Determination of tissue plasminogen activator and its "fast" inhibitor in plasma. Clin Chem 1986; 32: 482-5.
15. Rånby M, Nguyen G, Scarabin PY, Samama M. Immunoreactivity of tissue plasminogen activator and its inhibitor complexes: Biochemical and multicenter validation of a two-site immunosorbent assay. Thromb Haemost 1989; 61: 409-14.
16. Juhan-Vague I, Moerman B, De Cock F, Aillaud MF, Collen D. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb Res 1984; 33: 523-30.
17. Jansson J-H, Norberg B, Nilsson TK Impact of acute phase on concentrations of tissue plasminogen activator and plasminogen activator inhibitor in plasma after deep-vein thrombosis or open-heart surgery. Clin Chem 1989; 35: 1544-5.
18. Åberg M, Nilsson IM. Fibrinolytic response to venous occlusion and vasopressin in health and thrombotic disease. Progr Chem Fibr Thromb 1975; 1: 121-9.
19. Petäjä J. Fibrinolytic response to venous occlusion for 10 and 20 minutes in healthy subjects and in patients with deep vein thrombosis. Thromb Res 1989; 56: 251-63.
20. Brommer EJP, Barrett-Bergshoeff MM, Allen RA, Schicht I, Bertina RM, Schalekamp MADH The use of desmopressin acetate (DDAVP) as a test of the fibrinolytic capacity of patients - analysis of responders and non-responders. Thromb Haemost 1982; 48: 156-61.
21. Smith P, Arnesen H, Dahl KH, Nilsen DWT, Opstad T, Andersen P. A comparative study of venous occlusion and DDAVP stimulated fibrinolysis in normolipidemic subjects. Thromb Res 1988; 52: 655-60.
22. Hadjez JM, Combe S, Horellou MH, Conard J, Nguyen G, Van Dreden P, Samama M. Heterogeneous mechanisms responsible for reduced fibrinolytic capacity in patients with a history of venous thrombosis. Fibrinolysis 1994; 8: 87-95.
23. Rånby M, Bergsdorf N, Nilsson T, Mellbring G, Winblad B, Bucht G. Age dependence of tissue plasminogen activator concentrations in plasma, as studied by an improved enzyme-linked immunosorbent assay. Clin Chem 1986; 32: 2160-5.
24. Aillaud MF, Pignol F, Alessi MC, Harle JR, Escande M, Mongin M, Juhan-Vague I. Increase in plasma concentration of plasminogen activator inhibitor, fibrinogen von Willebrand factor, Factor VIII: C and erythrocyte sedimentation rate with age. Thromb Haemost 1986; 55: 330-2.
25. Hashimoto Y, Kobayashi A, Yamazaki N, Sugawara Y, Takada Y, Takada A. Relationship between age and plasma tPA, PA-inhibitor, and PA-activity. Thromb Res 1987; 46: 625-33.
26. Sundell IB, Nilsson TK, Rånby M, Hallmans G, Hellsten G. Fibrinolytic variables are related to age, sex, blood pressure, and body build measurements: a cross-sectional study in Norsjö; Sweden. J Clin Epidemiol 1989; 42: 719-23.